Apolipoprotein(a) kringle IV type 7-8 domain (Apo(a) KIV7-8) (Apo(a) KIV7-8)

Apolipoprotein(a) kringle IV type 7-8 domain (Apo(a) KIV7-8) is a specialized structural motif within Apolipoprotein(a), the protein component that distinguishes Lipoprotein(a) [Lp(a)] from low-density lipoprotein (LDL). These specific kringle domains are essential for the assembly of the Lp(a) particle, as they mediate the initial non-covalent recognition and binding to Apolipoprotein B-100 (ApoB-100) on LDL-like particles (Source: Nature, 2023, doi:10.1038/s41586-023-06387-2). This interaction is a mandatory step before the formation of a permanent disulfide bridge that stabilizes the Lp(a) complex. High plasma concentrations of Lp(a) are strongly associated with an increased risk of myocardial infarction, stroke, and aortic stenosis due to its pro-inflammatory, pro-atherogenic, and potentially pro-thrombotic properties (Source: JACC, 2022, doi:10.1016/j.jacc.2022.07.001). Traditional therapies like statins do not effectively lower Lp(a), making the KIV7-8 domain an attractive target for drug development. Small molecule inhibitors, such as Muvalaplin, are designed to bind specifically to the lysine-binding sites within these domains to disrupt the assembly of Lp(a) (Source: JAMA, 2023, doi:10.1001/jama.2023.16503). By preventing the formation of the pro-atherogenic and pro-thrombotic Lp(a) complex, targeting these domains offers a novel approach to reducing cardiovascular risk in patients with high Lp(a) concentrations. This mechanism is distinct from antisense or siRNA approaches, as it targets the protein-protein interaction directly rather than protein synthesis (Source: PubMed, PMID: 37642487). The specificity for KIV7-8 is vital to avoid interfering with the structurally similar kringle domains of plasminogen, thereby maintaining normal fibrinolytic activity.

Other names

Apolipoprotein(a) KIV7-8LPA KIV7-8Kringle IV type 7 and 8 domains of Apolipoprotein(a)Apo(a) KIV7-KIV8Apolipoprotein(a) lysine-binding site

Inhibition of Lipoprotein(a) assembly by disrupting the non-covalent interaction between Apolipoprotein(a) and Apolipoprotein B-100